Ser78

Site Information
PAysRALsRQLssGV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448402

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 36 , 83 , 89 , 93 ) , [32P] bio-synthetic labeling ( 89 , 93 ) , immunoassay ( 3 , 6 , 8 , 13 ) , immunoprecipitation ( 39 , 65 , 67 ) , mass spectrometry ( 12 , 16 , 18 , 19 , 20 , 22 , 24 , 26 , 27 , 28 , 30 , 32 , 33 , 34 , 36 , 37 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 78 , 81 , 84 ) , mutation of modification site ( 2 , 4 , 5 , 7 , 9 , 10 , 11 , 12 , 17 , 25 , 31 , 39 , 52 , 65 , 77 , 86 , 87 , 88 , 93 ) , peptide sequencing ( 89 , 93 ) , phospho-antibody ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 17 , 20 , 21 , 31 , 36 , 38 , 65 , 67 , 77 , 79 , 80 , 83 , 86 , 87 ) , phosphoamino acid analysis ( 93 ) , western blotting ( 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 14 , 15 , 17 , 20 , 21 , 31 , 36 , 38 , 52 , 65 , 67 , 77 , 79 , 80 , 83 , 87 )
Disease tissue studied:	atrial fibrillation ( 75 ) , bone cancer ( 42 ) , osteosarcoma ( 42 ) , brain cancer ( 20 ) , glioblastoma ( 20 ) , glioma ( 20 ) , breast cancer ( 17 , 21 , 24 , 33 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 83 , 87 ) , breast ductal carcinoma ( 17 , 68 , 69 , 70 , 71 ) , HER2 positive breast cancer ( 19 ) , luminal A breast cancer ( 19 ) , luminal B breast cancer ( 19 ) , breast cancer, triple negative ( 19 ) , cervical cancer ( 44 ) , cervical adenocarcinoma ( 44 ) , colorectal cancer ( 2 , 36 ) , colorectal carcinoma ( 2 , 36 ) , leukemia ( 39 , 81 ) , acute myelogenous leukemia ( 39 ) , chronic myelogenous leukemia ( 81 ) , liver cancer ( 47 , 77 ) , hepatocellular carcinoma ( 77 ) , liver cancer, surrounding tissue ( 46 ) , lung cancer ( 28 , 33 , 43 , 45 , 67 ) , non-small cell lung cancer ( 33 , 43 ) , non-small cell lung adenocarcinoma ( 28 , 45 ) , small-cell lung cancer ( 67 ) , neuroblastoma ( 32 ) , OSCC ( 10 ) , ovarian cancer ( 67 ) , pancreatic cancer ( 9 ) , pancreatic carcinoma ( 9 ) , pancreatic ductal adenocarcinoma ( 9 , 27 ) , prostate cancer ( 67 , 79 ) , melanoma skin cancer ( 48 , 49 , 62 , 67 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 37 , 86 ) , 'pancreatic, ductal'-pancreas ( 27 ) , 'stem, induced pluripotent' ( 7 ) , 293 (epithelial) ( 65 ) , A549 (pulmonary) [CD38 (human), transfection, Lentiviral particles containing CD38 vector were transfected] ( 18 ) , A549 (pulmonary) ( 18 ) , BEAS-2B (epithelial) ( 14 ) , breast ( 17 , 19 , 72 , 73 , 74 , 83 ) , BT-20 (breast cell) ( 33 ) , BT-474 (breast cell) ( 17 , 83 ) , BT-549 (breast cell) ( 33 ) , Cal27 (squamous) ( 10 ) , Calu 6 (pulmonary) ( 33 ) , Caov-3 (ovarian) ( 67 ) , Dede (fibroblast) ( 93 ) , DLD1 (intestinal) ( 36 ) , EA.hy 926 (endothelial) ( 12 ) , endothelial-aorta ( 34 ) , fibroblast-skin ( 84 ) , G361 (melanocyte) ( 67 ) , glial-brain ( 20 ) , H2009 (pulmonary) ( 33 ) , H2077 (pulmonary) ( 33 ) , H2887 (pulmonary) ( 33 ) , H322M (pulmonary) ( 33 ) , H413 ( 8 ) , HCC1359 (pulmonary) ( 33 ) , HCC1937 (breast cell) ( 33 ) , HCC2279 (pulmonary) ( 33 ) , HCC366 (pulmonary) ( 33 ) , HCC4006 (pulmonary) ( 33 ) , HCC78 (pulmonary) ( 33 ) , HCC827 (pulmonary) ( 33 ) , HCT116 (intestinal) ( 2 ) , HDMEC (endothelial) ( 12 ) , heart ( 75 ) , HeLa (cervical) ( 3 , 4 , 5 , 22 , 31 , 38 , 41 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 63 , 64 , 65 , 78 , 93 ) , HeLa S3 (cervical) ( 44 ) , HiB5 (neuron) ( 88 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 24 ) , HMLER ('stem, breast cancer') ( 24 ) , HN6 (endothelial) ( 10 ) , HOP62 (pulmonary) ( 33 ) , Huh7 (hepatic) ( 77 ) , HUVEC (endothelial) ( 1 , 12 , 67 , 80 ) , JIMT-1 (breast cell) ( 17 ) , K562 (erythroid) ( 30 , 81 ) , LCLC-103H (pulmonary) ( 33 ) , liver ( 26 , 46 , 47 , 77 ) , LNCaP (prostate cell) ( 79 ) , LOU-NH91 (squamous) ( 33 ) , lung ( 28 , 43 ) , MCF-7 (breast cell) ( 33 , 67 , 68 , 69 , 70 , 71 ) , MDA-MB-231 (breast cell) ( 21 , 33 ) , MDA-MB-435 (breast cell) ( 67 ) , MDA-MB-468 (breast cell) ( 33 ) , MIA PaCa-2 (pancreatic) ( 9 ) , myocyte-heart ( 11 ) , NB10 (neural crest) ( 32 ) , NCI-H1395 (pulmonary) ( 33 ) , NCI-H1568 (pulmonary) ( 33 ) , NCI-H157 (pulmonary) ( 33 ) , NCI-H1648 (pulmonary) ( 33 ) , NCI-H1650 (pulmonary) ( 50 , 51 ) , NCI-H1666 (pulmonary) ( 33 ) , NCI-H1703 (squamous) ( 76 ) , NCI-H2030 (pulmonary) ( 33 ) , NCI-H2172 (pulmonary) ( 33 ) , NCI-H322 (pulmonary) ( 33 ) , NCI-H3255 (pulmonary) ( 45 , 60 , 61 , 66 ) , NCI-H460 (pulmonary) ( 33 ) , NCI-H520 (squamous) ( 33 ) , NCI-H647 (pulmonary) ( 33 ) , NPC (neural crest) ( 32 ) , OH-1 (pulmonary) ( 67 ) , Pa01C (pancreatic) ( 9 ) , PC3 (prostate cell) ( 67 ) , PC9 (pulmonary) ( 33 ) , platelet ( 6 , 15 ) , platelet-blood ( 89 ) , PLB985 (myeloid) ( 7 ) , REG ( 52 ) , skin ( 13 , 48 , 49 , 62 ) , SKOV-3 (ovarian) ( 67 ) , THP1 (myeloid) ( 39 ) , U2OS (bone cell) ( 42 ) , Vero E6-S ('epithelial, kidney') ( 16 )

Upstream Regulation
Regulatory protein:	AR (human) ( 79 ) , BMP10 (human) ( 1 ) , CD38 (human) ( 18 ) , CLN3 (human) ( 3 ) , CLPB (human) ( 7 ) , DSG3 (human) ( 8 ) , GADD45B (human) ( 1 ) , GDF2 (human) ( 1 ) , HAX1 (human) ( 7 ) , MAPKAPK2 (human) ( 65 ) , MAPKAPK3 (human) ( 12 ) , P38A ( 12 ) , P38A (human) ( 67 ) , SMAD4 (human) ( 1 , 10 )
Putative in vivo kinases:	MAPKAPK2 (human) ( 9 , 12 ) , P70S6KB (human) ( 93 )
Kinases, in vitro:	MAPKAPK2 (human) ( 12 , 90 , 91 , 92 ) , PKACA (human) ( 90 ) , PKG1 iso2 (human) ( 90 )
Treatments:	5-iodotubercidin ( 82 ) , ACh ( 86 ) , actinomycin_D ( 1 ) , adriamycin ( 38 ) , ADT ( 67 , 80 ) , ara-a ( 82 ) , arsenite ( 93 ) , ATI-450 ( 9 ) , bacterial infection ( 14 ) , Bay61-3606 ( 14 ) , bicalutamide ( 79 ) , BIRB-0796 ( 14 ) , calyculin_A ( 82 ) , CID755673 ( 9 ) , circRNA ( 10 ) , cisplatin ( 38 ) , collagen ( 6 , 15 ) , CXCL12 ( 6 , 15 ) , D3T ( 67 , 80 ) , diclofenac ( 80 ) , DRB ( 1 ) , FGF2 ( 93 ) , FIRINOX ( 9 ) , FLUVOXAMINE_MALEATE ( 6 ) , Go_6983 ( 9 ) , H2O2 ( 80 ) , HA-1077 ( 6 ) , heat_shock ( 5 , 93 ) , heating ( 21 ) , heregulin ( 83 ) , histamine ( 12 ) , IL-1b ( 65 ) , J2 ( 12 , 17 ) , LLOMe ( 4 ) , LY2228820 ( 9 ) , menadione ( 31 ) , metribolone ( 79 ) , mutation ( 31 ) , nerve_damage ( 87 ) , nocodazole ( 44 ) , NSC23766 ( 6 ) , OSU-03012 ( 20 ) , PAR1-activating_peptide ( 12 ) , PD98059 ( 79 , 82 ) , PF3622044 ( 1 ) , PF3644022 ( 12 ) , phorbol_ester ( 93 ) , S-diclofenac ( 80 ) , S-sulindac ( 80 ) , S-valproate ( 80 ) , SB202190 ( 65 ) , SB203347 ( 79 ) , SB203580 ( 1 , 5 , 12 , 14 , 15 , 67 , 79 , 82 , 83 ) , serum ( 93 ) , siRNA ( 7 , 9 , 12 , 65 ) , SN-38 ( 9 ) , sodium_hydrosulfide ( 80 ) , SP600125 ( 67 ) , spermine-NONOate ( 80 ) , sulindac ( 80 ) , taxol ( 41 ) , thiolutin ( 67 ) , thrombin ( 12 , 89 , 93 ) , TNF ( 93 ) , Tramadol ( 6 ) , trastuzumab ( 17 ) , UVB ( 8 ) , valproic acid ( 80 ) , vorapaxar ( 12 ) , Y27632 ( 6 )

Downstream Regulation
Effects of modification on HSP27:	activity, induced ( 88 ) , enzymatic activity, inhibited ( 2 ) , intracellular localization ( 4 , 88 ) , molecular association, regulation ( 2 , 10 , 11 , 12 , 17 , 39 , 52 , 65 , 86 ) , phosphorylation ( 11 , 77 ) , protein conformation ( 85 ) , protein degradation ( 39 ) , sumoylation ( 52 ) , ubiquitination ( 65 )
Effects of modification on biological processes:	apoptosis, altered ( 77 ) , apoptosis, inhibited ( 9 , 11 , 17 , 87 ) , autophagy, induced ( 4 ) , autophagy, inhibited ( 2 ) , carcinogenesis, induced ( 8 , 9 , 10 , 17 ) , cell cycle regulation ( 67 ) , cell differentiation, induced ( 7 ) , cell growth, altered ( 77 ) , cell growth, induced ( 10 , 17 ) , cell motility, induced ( 8 , 10 ) , cytoskeletal reorganization ( 90 ) , signaling pathway regulation ( 10 , 11 ) , transcription, altered ( 77 ) , transcription, inhibited ( 11 )
Induce interaction with:	HER2 (human) ( 17 ) , LASS1 (human) ( 2 ) , TPM1 (human) ( 86 ) , p53 (human) ( 11 )
Inhibit interaction with:	HSF1 (human) ( 52 ) , HSP27 (human) ( 12 ) , RNA ( 10 ) , TRAF6 (human) ( 65 ) , hnRNP D0 (human) ( 39 )

Disease / Diagnostics Relevance
Relevant diseases:	breast cancer ( 83 ) , DCM ( 11 )

References
1	Al Tarrass M, et al. (2024) Large-scale phosphoproteomics reveals activation of the MAPK/GADD45β/P38 axis and cell cycle inhibition in response to BMP9 and BMP10 stimulation in endothelial cells. Cell Commun Signal 22, 158 38439036 Curated Info
2	Boyd RA, et al. (2023) The heat shock protein Hsp27 controls mitochondrial function by modulating ceramide generation. Cell Rep 42, 113081 37689067 Curated Info
3	Relton EL, et al. (2023) The Batten disease protein CLN3 is important for stress granules dynamics and translational activity. J Biol Chem 299, 104649 36965618 Curated Info
4	Gallagher ER, Holzbaur ELF (2023) The selective autophagy adaptor p62/SQSTM1 forms phase condensates regulated by HSP27 that facilitate the clearance of damaged lysosomes via lysophagy. Cell Rep 42, 112037 36701233 Curated Info
5	Adriaenssens E, et al. (2023) Small heat shock proteins operate as molecular chaperones in the mitochondrial intermembrane space. Nat Cell Biol 36690850 Curated Info
6	Iida H, et al. (2023) Tramadol regulates the activation of human platelets via Rac but not Rho/Rho-kinase. PLoS One 18, e0279011 36638092 Curated Info
7	Fan Y, et al. (2022) HAX1-dependent control of mitochondrial proteostasis governs neutrophil granulocyte differentiation. J Clin Invest 132 35499078 Curated Info
8	Ahmad US, Parkinson EK, Wan H (2022) Desmoglein-3 induces YAP phosphorylation and inactivation during collective migration of oral carcinoma cells. Mol Oncol 16 35000271 Curated Info
9	Grierson PM, et al. (2021) The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Sci Transl Med 13, eabb5445 34851698 Curated Info
10	Ju H, et al. (2021) A novel intronic circular RNA, circGNG7, inhibits head and neck squamous cell carcinoma progression by blocking the phosphorylation of heat shock protein 27 at Ser78 and Ser82. Cancer Commun (Lond) 34498800 Curated Info
11	Kanagasabai R, Karthikeyan K, Zweier JL, Ilangovan G (2021) Serine Mutations in Hsp27 abrogate its ability to inhibit p53 dependent apoptosis and Doxorubicin-induced Heart Failure in mice. Am J Physiol Heart Circ Physiol 34477462 Curated Info
12	Rada CC, et al. (2021) Heat shock protein 27 activity is linked to endothelial barrier recovery after proinflammatory GPCR-induced disruption. Sci Signal 14, eabc1044 34516752 Curated Info
13	Bozó R, et al. (2021) Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin. Life (Basel) 11 34201431 Curated Info
14	Coates MS, et al. (2021) Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway. PLoS One 16, e0246050 33524056 Curated Info
15	Nakashima D, et al. (2020) Synergistic effect of collagen and CXCL12 in the low doses on human platelet activation. PLoS One 33119719 Curated Info
16	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
17	Hwang SY, et al. (2020) Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance. Cancers (Basel) 32545363 Curated Info
18	Wang W, et al. (2018) Decreased NAD Activates STAT3 and Integrin Pathways to Drive Epithelial-Mesenchymal Transition. Mol Cell Proteomics 29980616 Curated Info
19	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
20	Booth L, et al. (2016) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7, 12975-96 26887051 Curated Info
21	Morlé A, Garrido C, Micheau O (2015) Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. Cell Death Dis 6, e1633 25675293 Curated Info
22	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
23	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
24	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
25	Kötter S, et al. (2014) Human myocytes are protected from titin aggregation-induced stiffening by small heat shock proteins. J Cell Biol 204, 187-202 24421331 Curated Info
26	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
27	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
28	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
29	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
30	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
31	Simon S, et al. (2013) Analysis of the Dominant Effects Mediated by Wild Type or R120G Mutant of αB-crystallin (HspB5) towards Hsp27 (HspB1). PLoS One 8, e70545 23950959 Curated Info
32	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
33	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
34	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
35	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
36	Sakai A, et al. (2012) Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics 75, 806-18 21989268 Curated Info
37	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
38	Gibert B, et al. (2011) Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 30, 3672-81 21423207 Curated Info
39	Knapinska AM, et al. (2011) Chaperone Hsp27 modulates AUF1 proteolysis and AU-rich element-mediated mRNA degradation. Mol Cell Biol 31, 1419-31 21245386 Curated Info
40	Chang E, et al. (2011) MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood 117, 2527-37 21131586 Curated Info
41	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
42	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
43	Rikova K (2010) CST Curation Set: 9019; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
44	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
45	Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64 20736484 Curated Info
46	Tucker M (2009) CST Curation Set: 8744; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
47	Tucker M (2009) CST Curation Set: 8747; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
48	Tucker M (2009) CST Curation Set: 8387; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
49	Tucker M (2009) CST Curation Set: 8367; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
50	Possemato A (2009) CST Curation Set: 8048; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
51	Possemato A (2009) CST Curation Set: 8049; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
52	Brunet Simioni M, et al. (2009) Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity. Oncogene 28, 3332-44 19597476 Curated Info
53	Zhou J (2009) CST Curation Set: 7637; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
54	Zhou J (2009) CST Curation Set: 7618; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
55	Zhou J (2009) CST Curation Set: 7617; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
56	Zhou J (2009) CST Curation Set: 7615; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
57	Zhou J (2009) CST Curation Set: 7614; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
58	Zhou J (2009) CST Curation Set: 7616; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
59	Zhou J (2009) CST Curation Set: 7613; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
60	Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
61	Possemato A (2009) CST Curation Set: 7416; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
62	Tucker M (2009) CST Curation Set: 6436; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
63	Zhou J (2009) CST Curation Set: 6346; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
64	Zhou J (2009) CST Curation Set: 6345; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
65	Wu Y, et al. (2009) HSP27 regulates IL-1 stimulated IKK activation through interacting with TRAF6 and affecting its ubiquitination. Cell Signal 21, 143-50 18950704 Curated Info
66	Moritz A (2008) CST Curation Set: 5613; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
67	Dai S, et al. (2008) Comprehensive characterization of heat shock protein 27 phosphorylation in human endothelial cells stimulated by the microbial dithiole thiolutin. J Proteome Res 7, 4384-95 18720982 Curated Info
68	Possemato A (2008) CST Curation Set: 5244; Year: 2008; Biosample/Treatment: cell line, MCF-7/untreated; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
69	Possemato A (2008) CST Curation Set: 5240; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
70	Possemato A (2008) CST Curation Set: 5242; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
71	Possemato A (2008) CST Curation Set: 5241; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
72	Tucker M (2008) CST Curation Set: 5205; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
73	Tucker M (2008) CST Curation Set: 5192; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
74	Tucker M (2008) CST Curation Set: 5193; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
75	Stokes M (2008) CST Curation Set: 5095; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
76	Moritz A (2008) CST Curation Set: 4978; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
77	Matsushima-Nishiwaki R, et al. (2008) Phosphorylated heat shock protein 27 represses growth of hepatocellular carcinoma via inhibition of extracellular signal-regulated kinase. J Biol Chem 283, 18852-60 18477563 Curated Info
78	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info
79	Zoubeidi A, et al. (2007) Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67, 10455-65 17974989 Curated Info
80	Isenberg JS, et al. (2007) Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151, 63-72 17351657 Curated Info
81	Possemato A (2007) CST Curation Set: 2722; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
82	Lerea KM, Venjara AY, Olson SC, Kelly MR (2007) Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 5'-iodotubercidin. Biochim Biophys Acta 1773, 185-91 17052767 Curated Info
83	Zhang D, Wong LL, Koay ES (2007) Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer. Mol Cancer 6, 52 17697330 Curated Info
84	Yang F, et al. (2006) Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res 5, 1252-60 16674116 Curated Info
85	Lelj-Garolla B, Mauk AG (2005) Self-association of a small heat shock protein. J Mol Biol 345, 631-42 15581903 Curated Info
86	Somara S, Bitar KN (2004) Tropomyosin interacts with phosphorylated HSP27 in agonist-induced contraction of smooth muscle. Am J Physiol Cell Physiol 286, C1290-301 14749215 Curated Info
87	Benn SC, et al. (2002) Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival. Neuron 36, 45-56 12367505 Curated Info
88	Geum D, Son GH, Kim K (2002) Phosphorylation-dependent cellular localization and thermoprotective role of heat shock protein 25 in hippocampal progenitor cells. J Biol Chem 277, 19913-21 11912188 Curated Info
89	MacDonald JA, Mackey AJ, Pearson WR, Haystead TA (2002) A strategy for the rapid identification of phosphorylation sites in the phosphoproteome. Mol Cell Proteomics 1, 314-22 12096113 Curated Info
90	Butt E, et al. (2001) Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 276, 7108-13 11383510 Curated Info
91	Rogalla T, et al. (1999) Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274, 18947-56 10383393 Curated Info
92	Stokoe D, et al. (1992) Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 313, 307-13 1332886 Curated Info
93	Landry J, et al. (1992) Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem 267, 794-803 1730670 Curated Info